VALE3 has dropped 11.4% over the past month to BRL 69.61, its sharpest compression in recent months, arriving at a setup where cheap multiples meet deteriorating earnings momentum ahead of an October 29 result.
The most striking feature of the current setup is the valuation. Vale trades on a trailing P/E of just under 8x and an EV/EBITDA of 4.5x, both of which have contracted meaningfully over the past 30 days. The P/E is down nearly a full turn from a month ago. The price-to-book has slipped to 1.38x. For a company with a dividend yield implied by a DPS/price ratio of 6.5% and an EV/EBIT factor score ranking in the 100th percentile of its universe, the numbers look cheap. The problem is that "cheap" has a reason: forward EPS momentum scores near the bottom of the universe, placing in the 2nd percentile on 12-month forward year-on-year EPS growth and the 14th percentile on 90-day EPS momentum. Earnings expectations are moving the wrong way, and the stock is re-rating accordingly.
Positioning in the lending market offers no drama at all. Availability is effectively unconstrained, with roughly 69 million shares available to borrow and near-zero demand from short sellers. Cost to borrow is a negligible 0.53% on the most recent reading, down sharply from 1.62% in early August, though that data is now a month old. The ORTEX short score sits at 25.1, a low reading placing Vale in the 97th percentile for "not shorted" relative to peers: short sellers have largely left this name alone. That is a two-edged signal. It removes the risk of a short squeeze but also strips out a potential floor from covering activity. There is no meaningful squeeze pressure, no tight borrow, and no sign that the short-side is building a thesis here.
The ownership picture is more interesting than the lending market. Capital Research and Management holds 9.1% of shares, and BlackRock has added 83.8 million shares in its most recently reported period to reach 8.7%. The Brazilian pension fund PREVI holds a further 7.3%, and Mitsui holds 6.7% with no change. The top four holders alone account for roughly 32% of the register. BlackRock's addition is the standout move: building nearly 84 million shares into a declining stock while it trades at the low end of its recent valuation range is a notable positioning decision from one of the world's largest index and active managers. Insider activity from Brazilian board-adjacent entities is limited to tiny token purchases totalling a few hundred reais and carries no informational weight.
Peer moves reinforce the sense that this is a sector-wide pressure rather than a Vale-specific story. Closest correlate BRAP3 fell 4.3% on the week, nearly in line with Vale's 4.4% slide. FCX dropped 4.8% and TECK.B fell 5.1%. Gold-weighted names OR and PAAS took bigger hits of 8.1% and 8.5% respectively, partly on metal-price moves. The common thread across the group is commodity price pressure, and Vale's heavier concentration in iron ore, the weakest of the major metals this year, explains why it has underperformed the diversified names on a one-month basis while broadly tracking peers week to week.
The dividend is a genuine counterweight. Vale paid BRL 0.46 per share in August, a continuation of a programme that has delivered substantially larger amounts historically. At a 6.5% implied yield on current prices, income-oriented holders have a reason to stay, and the dividend score at the 91st percentile reflects that. The Q3 result on October 29 will be the next real test: the market will want to know whether iron ore production guidance, already trimmed earlier this year, is stabilising, and whether the soft demand environment out of China is showing any sign of bottoming. That, more than the multiples or the lending market, is the number that will move the stock next.
See the live data behind this article on ORTEX.
Open VALE3 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
